Identification of key candidate genes and pathways associated with colorectal aberrant crypt foci-to-adenoma-to-carcinoma progression
Gastroenterology and Hepatology from Bed to Bench,
Vol. 14 No. Supplement 1 (2021),
30 December 2021
https://doi.org/10.22037/ghfbb.vi.2205
Abstract
Aim: The present study aimed to detect key candidate genes and pathways involved in colorectal aberrant crypt foci-to-adenoma-to-carcinoma progression.
Background: Although colorectal cancer (CRC) is the third most common type of cancer, the involved signaling pathways and driver-genes remain largely unclear. CRC begins with the malignant transformation of precancerous lesions including aberrant crypt foci (ACF) and benign adenomatous polyp or adenoma
Methods: A list of formerly reported ACF, adenoma, and CRC-associated proteins was obtained from GeneCards, and then the data in online David Bioinformatics Resources was analyzed. The protein-protein interactions were surveyed utilizing String database and Cytoscape software. After hubs and bottlenecks were recognized, the key genes and pathways were identified through different bioinformatics analysis.
Results The most important pathways associated with colorectal aberrant crypt foci-to-adenoma progression were attributed to “pathways in cancer” and “chemokine signaling pathway” and those in adenoma-to-carcinoma progression were related to “pathways in cancer,” “chemokine signaling pathway,” and “Ras signaling pathway.” The genes participating in these pathways are key ones. Furthermore, PRKACB, CUL2, and GSK3B were significant as the seed in the clusters related to adenoma and GNB1, RALBP1, ROCK1, and IKBKG in the clusters related to cancer.
Conclusion: The key candidate genes and pathways in progress CRC formed precursor lesions were identified by integrated bioinformatics analysis. The results could lead to a better understanding of the cause and underlying molecular events as well as detection of therapeutic targets for CRC.
- Aberrant Crypt Foci, Adenomatous polyp, Colorectal Cancer, Key Genes and Pathways.
How to Cite
References
1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet (London, England). 2005;365(9454):153-65.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5):E359-E86.
3. Alrawi SJ, Schiff M, Carroll RE, Dayton M, Gibbs JF, Kulavlat M, et al. Aberrant crypt foci. Anticancer research. 2006;26(1a):107-19.
4. Ma YL, Peng JY, Zhang P, Huang L, Liu WJ, Shen TY, et al. Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. Journal of proteome research. 2009;8(10):4525-35.
5. Tanaka T, Tanaka M, Tanaka T, Ishigamori R. Biomarkers for colorectal cancer. International journal of molecular sciences. 2010;11(9):3209-25.
6. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Harford WV, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. New England Journal of Medicine. 2000;343(3):162-8.
7. Ward D, Suggett N, Cheng Y, Wei W, Johnson H, Billingham L, et al. Identification of serum biomarkers for colon cancer by proteomic analysis. British journal of cancer. 2006;94(12):1898.
8. Hauptman N, Bostjancic E, Zlajpah M, Rankovic B, Zidar N. Bioinformatics Analysis Reveals Most Prominent Gene Candidates to Distinguish Colorectal Adenoma from Adenocarcinoma. BioMed research international. 2018;2018:9416515.
9. Guo Y, Bao Y, Ma M, Yang W. Identification of Key Candidate Genes and Pathways in Colorectal Cancer by Integrated Bioinformatical Analysis. International journal of molecular sciences. 2017;18(4).
10. Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncology letters. 2018;16(1):9-18.
11. Druliner BR, Wang P, Bae T, Baheti S, Slettedahl S, Mahoney D, et al. Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. Sci Rep. 2018;8(1):3161.
12. Zhou D, Yang L, Zheng L, Ge W, Li D, Zhang Y, et al. Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. PloS one. 2013;8(1):e53310.
13. Cheng L, Lai M-D. Aberrant crypt foci as microscopic precursors of colorectal cancer. World journal of gastroenterology: WJG. 2003;9(12):2642.
14. Quintanilla I, Lopez-Ceron M, Jimeno M, Cuatrecasas M, Zabalza M, Moreira L, et al. Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk. Clinical and translational gastroenterology. 2019;10(6):e00047.
15. Lopez-Ceron M, Pellise M. Biology and diagnosis of aberrant crypt foci. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2012;14(4):e157-64.
16. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. New England Journal of Medicine. 1998;339(18):1277-84.
17. Orlando FA, Tan D, Baltodano JD, Khoury T, Gibbs JF, Hassid VJ, et al. Aberrant crypt foci as precursors in colorectal cancer progression. Journal of surgical oncology. 2008;98(3):207-13.
18. Roncucci L, Modica S, Pedroni M, Tamassia M, Ghidoni M, Losi L, et al. Aberrant crypt foci in patients with colorectal cancer. British journal of cancer. 1998;77(12):2343.
19. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer letters. 1995;93(1):55-71.
20. Strum WB. Colorectal adenomas. New England Journal of Medicine. 2016;374(11):1065-75.
21. Nagorni A, Katic V, Zivkovic V, Stanojevic G. Advanced colorectal adenoma. Arch Oncol. 2004;12(Suppl 1):59-60.
22. Langner C. Serrated and non-serrated precursor lesions of colorectal cancer. Digestive diseases (Basel, Switzerland). 2015;33(1):28-37.
23. Dulal S, Keku TO. Gut microbiome and colorectal adenomas. Cancer J. 2014;20(3):225-31.
24. Bonnington SN, Rutter MD. Surveillance of colonic polyps: Are we getting it right? World journal of gastroenterology. 2016;22(6):1925-34.
25. Erim T, Rivas JM, Velis E, Castro F. Role of high definition colonoscopy in colorectal adenomatous polyp detection. World journal of gastroenterology: WJG. 2011;17(35):4001.
26. Buie WD, MacLean AR. Polyp surveillance. Clinics in colon and rectal surgery. 2008;21(04):237-46.
27. Robertson DJ, Greenberg ER, Beach M, Sandler RS, Ahnen D, Haile RW, et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology. 2005;129(1):34-41.
28. Scheen AJ. [OMICS AND BIG DATA, MAJOR ADVANCES TOWARDS PERSONALIZED MEDICINE OF THE FUTURE?]. Revue medicale de Liege. 2015;70(5-6):262-8.
29. Nambiar PR, Gupta RR, Misra V. An "Omics" based survey of human colon cancer. Mutation research. 2010;693(1-2):3-18.
30. Lin D, Zhang J, Li J, Xu C, Deng H-W, Wang Y-P. An integrative imputation method based on multi-omics datasets. BMC bioinformatics. 2016;17(1):247.
31. Chisanga D, Keerthikumar S, Pathan M, Ariyaratne D, Kalra H, Boukouris S, et al. Colorectal cancer atlas: an integrative resource for genomic and proteomic annotations from colorectal cancer cell lines and tissues. Nucleic acids research. 2015;44(D1):D969-D74.
32. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Current protocols in bioinformatics. 2016;54:1.30.1-1..3.
33. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols. 2009;4(1):44-57.
34. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, et al. STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37(Database issue):D412-6.
35. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003;13(11):2498-504.
36. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS computational biology. 2007;3(4):e59.
37. Itatani Y, Kawada K, Inamoto S, Yamamoto T, Ogawa R, Taketo M, et al. The role of chemokines in promoting colorectal cancer invasion/metastasis. International journal of molecular sciences. 2016;17(5):643.
38. Emmanouil G, Ayiomamitis G, Zizi-Sermpetzoglou A, Tzardi M, Moursellas A, Voumvouraki A, et al. Angiodrastic Chemokines in Colorectal Cancer: Clinicopathological Correlations. Analytical cellular pathology (Amsterdam). 2018;2018:1616973.
39. Marcuzzi E, Angioni R, Molon B, Cali B. Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization. International journal of molecular sciences. 2018;20(1).
40. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends in molecular medicine. 2010;16(3):133-44.
41. Cabrero-de Las Heras S, Martinez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World journal of gastroenterology. 2018;24(42):4738-49.
42. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. Journal of the National Cancer Institute. 2001;93(14):1062-74.
43. Zenonos K, Kyprianou K. RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol. 2013;5(5):97-101.
44. Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE, et al. RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia (New York, NY). 2008;10(7):680-6, 2 p following 6.
45. Soleimani A, Rahmani F, Saeedi N, Ghaffarian R, Khazaei M, Ferns GA, et al. The potential role of regulatory microRNAs of RAS/MAPK signaling pathway in the pathogenesis of colorectal cancer. Journal of cellular biochemistry. 2019.
46. Downward J. Targeting RAS signaling pathways in cancer therapy. Nature Reviews Cancer. 2003;3(1):11.
- Abstract Viewed: 13 times
- pdf Downloaded: 13 times